Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical Practice

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

NCT02431247 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS

NCT02155101 ·Status: COMPLETED ·Phase: PHASE3

Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals

NCT04097925 ·Status: COMPLETED ·Phase: PHASE2

Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals

NCT02503462 ·Status: TERMINATED ·Phase: PHASE4

Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta)

NCT02926456 ·Status: COMPLETED

Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects

NCT02404233 ·Status: UNKNOWN ·Phase: PHASE4

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

NCT01565850 ·Status: COMPLETED ·Phase: PHASE2

Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression

NCT02491242 ·Status: COMPLETED

Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts

NCT01928407 ·Status: COMPLETED ·Phase: PHASE4

Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection

NCT05527418 ·Status: RECRUITING ·Phase: PHASE2

Durvalumab in HIV-1 Patients With Solid Tumors

NCT03094286 ·Status: COMPLETED ·Phase: PHASE2

RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection

NCT04064632 ·Status: UNKNOWN ·Phase: PHASE4

A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/

NCT05421806 ·Status: ACTIVE_NOT_RECRUITING

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

NCT01968551 ·Status: COMPLETED ·Phase: PHASE3

Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.

NCT00849160 ·Status: COMPLETED ·Phase: PHASE3

DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection

NCT06203132 ·Status: RECRUITING ·Phase: PHASE3

National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection

NCT02987530 ·Status: COMPLETED ·Phase: PHASE3

HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain

NCT00685191 ·Status: COMPLETED ·Phase: PHASE4

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

NCT03227861 ·Status: COMPLETED ·Phase: PHASE3

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

NCT01449929 ·Status: COMPLETED ·Phase: PHASE3

Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals

NCT04079452 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients

NCT02384967 ·Status: COMPLETED ·Phase: PHASE2

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

NCT02269917 ·Status: COMPLETED ·Phase: PHASE3

Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance

NCT05506605 ·Status: UNKNOWN ·Phase: PHASE4

DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects

NCT01423812 ·Status: COMPLETED ·Phase: PHASE4